Following the second appraisal committee meeting on 8 May 2024, this appraisal has been paused because NICE needs additional time to reconsider, and analyse new information provided by the company (Vertex) about the complications associated with sickle cell disease which affects the basis for decision-making.
It is expected that a further committee meeting will be held to consider the additional information. We will update stakeholders and the NICE website when a committee meeting date is confirmed.